We have a global team of experienced veterinarians that have now treated many thousands of cases. Please feel free to contact us to answer any questions on case selection and management, or the clinical application of Arthramid® Vet.
FAQ’s- Case Selection & Management
Arthramid® Vet is used to treat non-infectious causes of joint lameness in animals, including both early and late stages of osteoarthritis (OA).
Arthramid® Vet is a biocompatible, non-absorbable, non-pyrogenic, neuro-innocuous injectable 2.5% cross-linked polyacrylamide hydrogel for intra-articular injection in animals. Arthramid® Vet consists of approximately 2.5% cross-linked polyacrylamide and 97.5% water for injection. The hydrogel is supplied in a sterile pre-filled 1 mL syringe sealed with a Luer lock fitting.
Arthramid® Vet hydrogel acts as a dynamic tissue scaffold that increases the elasticity and load transfer capacity of the joint, restoring the joint to healthy function.
Understanding the complexity of disease processes associated with joint pain remains a constant dilemma in clinical practice and as with any disease process, an accurate diagnosis is essential.
Arthritis describes inflammation of a joint and can occur after single or repetitive episodes of trauma. The term incorporates synovitis, capsulitis, sprain, intra-articular fractures, meniscal tears, and osteoarthritis(OA).
These pathological conditions are ‘a group of overlapping distinct diseases which may have different aetiologies, but with similar biologic, morphologic, and clinical outcomes.’
Although conventional concepts of OA emphasize the direct and predominant involvement of cartilage and bone in OA development, it is increasingly recognized that the synovium also contributes to the central pathophysiological event of cartilage matrix depletion.
Cases suitable for treatment with Arthramid® Vet are those in which lameness is localised to the joint by clinical examination, intra-articular analgesia, radiography, ultrasound, MRI, CT and/or Scintigraphy. Conditions that respond to treatment with Arthramid® Vet include acute and chronic synovitis, capsulitis, meniscal tears, OA, and subchondral bone cysts. It is essential that anamnesis of data of ongoing infection, concomitant medication, surgery or potential fracture is reviewed prior to injection to prevent possible infections or use of the product for conditions other than for which it is indicated.
Animals should be rested for 48 hours immediately after treatment. After this time the animal can return to exercise commiserate to its level of comfort.
Clinical studies show that tissue integration and subsequent augmentation of the joint capsule takes between 2 and 4 weeks to occur, although a response to treatment can be seen earlier than that in some cases.
Animals typically show a gradual reduction in lameness and synovitis during the first week after treatment and a concurrent reduction in reaction to passive flexion. This continues to improve over the ensuing 2 to 3 weeks. By 4 weeks no further improvement is expected. Re-examination at 4 weeks is therefore indicated to either administer a second dose in those that have only partially responded or to reassess
It is important for owners to understand the time lag for a treatment effect to be seen as this contrasts with conventional therapies. In this respect and due to its
Arthramid® Vet must be stored below 25°C (air conditioning) protected from direct sunlight. Do not freeze. Do not store unsealed syringes for later use.
Information To The Animal Owner
The owner of the animal should be informed about the indications, expected results, contraindications, precautions, warnings, and potential complications. The owner of the animal should be advised that in the case of post-application complications, the veterinarian who performed the Arthramid® Vet injections should be contacted immediately for necessary treatment.
Testimonials From Clinical Practice
Arthramid Vet New Zealand
Registered in New Zealand to: Innovative Medical Solutions Limited NZBN: 9429041325544, 32 Hill Road, Cambridge 3494, New Zealand. Registered pursuant to the ACVM Act 1997 Number A11596. See www.foodsafety.govt.nz for registration conditions.